<DOC>
	<DOCNO>NCT02036541</DOCNO>
	<brief_summary>To establish safety performance AqueSys XEN 45 Glaucoma Implant eye refractory glaucoma .</brief_summary>
	<brief_title>AqueSys XEN 45 Glaucoma Implant Refractory Glaucoma</brief_title>
	<detailed_description>A prospective , multi-center , single arm , open-label clinical trial evaluate safety IOP lower performance AqueSys XEN 45 Glaucoma Implant refractory glaucoma patient .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<criteria>Diagnosis Refractory Glaucoma Maximallytolerated medicate IOP two preoperative visit ≥20 mmHg ≤35 mmHg Visual field mean deviation score 3 dB bad Shaffer Angle Grade ≥ 3 Area free , healthy mobile conjunctiva target quadrant Active Neovascular Glaucoma Previous glaucoma shunt/valve target quadrant History corneal surgery , opacity disease/pathology Anticipated need ocular surgery Nonstudy eye BCVA 20/200 worse</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Glaucoma Implant</keyword>
	<keyword>Trabeculectomy</keyword>
	<keyword>POAG</keyword>
	<keyword>Primary Open Angle Glaucoma</keyword>
	<keyword>Pseudoexfoliation Glaucoma</keyword>
	<keyword>Pigmentary Glaucoma</keyword>
</DOC>